Masafumi Ihara
Masafumi Ihara publishes mostly in Neurology, Neurology and Epidemiology, on topics such as Acute Ischemic Stroke Management, Neurological Disease Mechanisms and Treatments and Cerebrovascular and Carotid Artery Diseases.
- World rank
- #252,123 of 7,710,434 ranked researchers
- Rank in Japan
- #2,010 of 383,136
- Works
- 605
- Citations
- 18k
- Citations per work
- 30.0
What does Masafumi Ihara research?
Masafumi Ihara's work is mostly in Medicine (45%), Neuroscience (15%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences26944.5%
- Medicine26944.5%
- Everything else24540.5%
- Life Sciences9115.0%
- Neuroscience9115.0%
- 1Neurology15% of their works
- 2Neurology15% of their works
- 3Epidemiology9% of their works
- 4Pulmonary and Respiratory Medicine9% of their works
- 5Psychiatry and Mental health6% of their works
- 6Cardiology and Cardiovascular Medicine6% of their works
Research topics
- Acute Ischemic Stroke Management
- Neurological Disease Mechanisms and Treatments
- Cerebrovascular and Carotid Artery Diseases
- Intracerebral and Subarachnoid Hemorrhage Research
- Cerebrovascular and genetic disorders
- Alzheimer's disease research and treatments
- Neurological Disorders and Treatments
- Moyamoya disease diagnosis and treatment
Which keywords describe Masafumi Ihara's research?
The keywords of their largest research topics: Oxidative Stress, Ischemic Stroke, Neuroprotection, White Matter Lesions, Microbleeds, Neuroinflammation, Endovascular Therapy and Thrombolysis.
- RNF213 Gene
- Citicoline
- Tau Pathology
- Notch3 receptor
- Intracerebral Hemorrhage
- Endarterectomy
- Vascular Cognitive Impairment
- Thrombolysis
- Neuroinflammation
- White Matter Lesions
- Ischemic Stroke
- Oxidative Stress
- Neuroprotection
- Microbleeds
- Endovascular Therapy
- Cerebral Hypoperfusion
- Carotid Artery Stenosis
- Cerebral Amyloid Angiopathy
- CADASIL
- Amyloid Hypothesis
- Cerebrolysin
- Moyamoya Disease
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 22 words, with their numbers
- Oxidative Stress2413 topics
- Ischemic Stroke1952 topics
- Neuroprotection1952 topics
- White Matter Lesions1912 topics
- Microbleeds1492 topics
- Neuroinflammation1392 topics
- Endovascular Therapy1351 topic
- Thrombolysis1351 topic
- Cerebral Hypoperfusion1181 topic
- Vascular Cognitive Impairment1181 topic
- Carotid Artery Stenosis1051 topic
- Endarterectomy1051 topic
- Cerebral Amyloid Angiopathy761 topic
- Intracerebral Hemorrhage761 topic
- CADASIL731 topic
- Notch3 receptor731 topic
- Amyloid Hypothesis631 topic
- Tau Pathology631 topic
- Cerebrolysin601 topic
- Citicoline601 topic
- Moyamoya Disease571 topic
- RNF213 Gene571 topic
Where does Masafumi Ihara work?
Masafumi Ihara's main affiliation in the publication record is National Cerebral and Cardiovascular Center, Japan.
How many publications and citations does Masafumi Ihara have?
OpenAlex counts 605 works and 18,146 citations for Masafumi Ihara, an h-index of 71, ranking #252,123 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Masafumi Ihara. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.